[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Saskatchewan\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":631},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,26,0,25,[9,44,69,92,110,135,156,175,205,233,261,284,308,330,351,371,396,423,446,478,500,527,554,576,605],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100638806","phase-1-intermittent-low-oxygen-breathing-a-first-study-testing-different-disease-stages-in-people-living-with-ms-100638806",false,"NCT07631143","Intermittent Low Oxygen Breathing: A First Study Testing Different Disease Stages in People Living With MS","Intermittent Low Oxygen Breathing: A First Study Testing Different Disease Stages in People Living With Multiple Sclerosis","LOxyMS","Inclusion Criteria:\n\n\\-\n\nGroup 1:\n\n* People with a confirmed diagnosis of MS and advanced disability level (Expanded Disability Status Scale (EDSS) \\>6.5 and \\\u003C9)\n* Without relapse for at least 90 days prior\n* Older than age 18\n\nGroup 2:\n\n* People with a confirmed diagnosis of relapsing remitting MS\n* Acute disabling relapse onset within the past 4 weeks. A disabling relapse will be defined as at least 1.0-point increase on the EDSS.\n* Older than age 18\n\nGroup 3:\n\n* People with a confirmed diagnosis of MS that is non-active and progressive (Primary or Secondary Progressive MS). Non-active will be defined as without MS relapse, new\u002Fenlarging or enhancing MRI lesions within the past 1 year.\n* EDSS \\\u003C=6.5\n* Older than age 18\n\nExclusion Criteria:\n\n* Pregnancy\n* Any of the following documented respiratory disorders: obstructive sleep apnea, chronic obstructive pulmonary disease, uncontrolled asthma, hypoxic pulmonary disease, respiratory infection in the previous 3 months\n* Ischemic cardiac disease\n* Cardiac arrhythmia\n* Severe hypertension (\\>160\u002F100)\n* Seizure disorders\n* Medically unstable in another capacity\n* Unable to provide informed consent","ALL","18 Years",{"count":21,"type":22},9,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","This study will look at the safety, tolerability and feasibility of a non-invasive treatment called Acute Intermittent Hypoxia (AIH) in people with Multiple Sclerosis (MS) at different stages of the disease course.",[29],"Multiple Sclerosis",[31],"Acute Intermittent Hypoxia","NOT_YET_RECRUITING","2026-06-02",{"date":35,"type":36},"2026-06-05","ACTUAL",{"date":38,"type":22},"2026-07-01",{"date":40,"type":22},"2028-08-01",{"name":42,"class":43},"University of Saskatchewan","OTHER",{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100637174","creatine-supplementation-during-glp-1a-therapy-100637174","NCT07625202","Creatine Supplementation During GLP-1a Therapy","A Pilot Study on Creatine Supplementation During Resistance-training for Prevention of Lean Tissue Mass Loss During GLP-1 Receptor Agonist Therapy","Inclusion Criteria:\n\n* Starting GLP-1 agonist therapy\n* 18 years of age or older\n\nExclusion Criteria:\n\n* Positive answers to a screening questionnaire for physical activity safety (the Get Active Questionnaire)",true,{"count":53,"type":22},40,[55],"NA","GLP-1 receptor agonists are effective for weight loss, but significant muscle mass is lost as a proportion of this weight loss. This study combines resistance-training and creatine supplementation to try to prevent this loss of muscle mass.",[58],"Sarcopenia","RECRUITING","2026-05-30",{"date":62,"type":36},"2026-06-04",{"date":64,"type":36},"2026-05-25",{"date":66,"type":22},"2027-12-31",{"name":42,"class":43},1,{"id":70,"slug":71,"hasResults":12,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":12,"sex":18,"minAge":77,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":23,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":4},"100637924","first-sask-study-protocol-a-remote-exercise-oncology-intervention-100637924","NCT07617220","FIRST-Sask Study Protocol: A Remote Exercise Oncology Intervention","FIRST-Sask Study Protocol: A Randomized Controlled Trial of a Remote Exercise Oncology Intervention","FIRST-Sask","Inclusion Criteria:\n\n* confirmed diagnosis of any type of cancer (except non-melanoma skin cancer);\n* having received cancer treatment within the past 12 months;\n* self-identifying as rural resident; or residing in areas outside of the city of Saskatoon or Regina;\n* age ≥65;\n* ability to communicate in English;\n* ability to provide informed consent;\n* physically suitable to participate by research personnel based on PAR-Q and physical performance screening.\n\nExclusion Criteria:\n\n* persistent light-headedness during physical activity of or syncopal episodes within the past month;\n* other comorbidities or musculoskeletal complications that preclude participation in the exercise programs as deemed by the exercise interventionist;\n* unstable bone metastases.","65 Years",{"count":79,"type":22},37,[55],"Older adults undergoing cancer treatment experience substantial treatment-related burden and reduced quality of life (QoL). Exercise is an effective supportive care intervention, but access is limited in rural and geographically dispersed settings. Evidence on flexible delivery models that accommodate patient preferences and real-world constraints remains scarce.\n\nThis study seeks to evaluate the feasibility and acceptability of a hybrid exercise program for older adults with cancer in rural settings and to obtain preliminary efficacy estimates to inform a larger trial. This randomized controlled trial tests a 12-week, multimodal exercise intervention co-designed with patient partners. The program uses a hybrid delivery model with options (in-person, remote, or combined formats) based on preference, geography, season, and alignment with routine travel (e.g. clinic visits). Older adults (≥65) with breast, lung, prostate, colorectal, or hematologic cancers are recruited using a multipronged strategy. Assessments at baseline and 12 weeks include cardiovascular endurance, upper and lower limb strength, balance, and QoL. Feasibility and acceptability will be examined via recruitment, retention, adherence, exit surveys and interviews. Exercise prescription will follow FITT principles. Adherence, dose modifications, and fidelity will be monitored using standardized procedures. Analyses will follow an intention-to-treat approach, with between-group and over-time effects estimated using generalized linear and mixed-effects models. This study will inform the development of a scalable exercise rehabilitation model to improve equitable access to supportive care in rural settings.",[83],"Exercise Oncology","2026-05-28",{"date":86,"type":36},"2026-06-01",{"date":88,"type":22},"2026-05",{"date":90,"type":22},"2027-07-30",{"name":42,"class":43},{"id":93,"slug":94,"hasResults":12,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":51,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":23,"phases":100,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":106,"completionDateStruct":107,"leadSponsor":109,"locationsCount":68},"100640865","n95-masks-for-lung-health-while-golfing-during-wildfire-season-100640865","NCT07620691","N95 Masks for Lung Health While Golfing During Wildfire Season","A Pilot \u002F Feasibility Study on Cardiorespiratory Health of Golfers During Wildfire Season","Inclusion Criteria:\n\n* Golf on a regular basis (two or more times per week)\n\nExclusion Criteria:\n\n* Smoker",{"count":53,"type":22},[55],"Lung health is negatively affected during wildfire season by increased smoke pollution. Wearing N95 masks protects lung health in the short-term. The purpose of our study is to assess whether wearing of N95 facemasks on days with moderate to high air pollution in people who go outside to golf on a regular basis (two or more times per week) for two months during the wildfire season projects lung health.",[103],"Bronchial Asthma","2026-05-26",{"date":33,"type":36},{"date":104,"type":36},{"date":108,"type":22},"2026-12-31",{"name":42,"class":43},{"id":111,"slug":112,"hasResults":12,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":51,"sex":18,"minAge":19,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":23,"phases":120,"briefSummary":121,"conditions":122,"keywords":124,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":134,"locationsCount":68},"100626288","saskatoon-berry-juice-for-muscle-recovery-100626288","NCT07433686","Saskatoon Berry Juice for Muscle Recovery","Effect of Short-term Saskatoon Berry Supplementation on Muscle Recovery","Inclusion Criteria:\n\n* Male or female\n* aged 18-35y\n\nExclusion Criteria:\n\n* Conditions that might be affects by exercise as determined by the \"Get Active Questionnaire\"","35 Years",{"count":119,"type":22},30,[55],"This study will evaluated the effect of Saskatoon berry juice on recovery from muscle-damaging exercise.",[123],"Muscle Damage",[125,126,127],"muscle damage","Saskatoon berries","strength","2026-04-27",{"date":130,"type":36},"2026-04-28",{"date":132,"type":36},"2026-02-26",{"date":108,"type":22},{"name":42,"class":43},{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":51,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":23,"phases":144,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":68},"100588816","dairy-vs-plant-based-beverages-for-improving-bone-health-during-exercise-100588816","NCT06946316","Dairy vs Plant-based Beverages for Improving Bone Health During Exercise","Dairy Versus Plant-based Beverages Combined With Resistance-training for Improving Bone Health","Inclusion Criteria:\n\n* Women need to be postmenopausal (no age limit)\n* Men need to be 50y or older\n\nExclusion Criteria:\n\n* Taking medications that might affect bone\n* Conditions that might preclude participating in a resistance-training program (determined by the \"Get Active Questionnaire\").\n* Planning 6 weeks of travel during the 12 month intervention period\n* Planning major surgery during the 12 month intervention period\n* Already strength training greater than 2 days per week for 30 minutes or longer per session\n* Allergies to ingredients in the beverages",{"count":143,"type":22},150,[55],"This study will evaluate the effects of consuming dairy milk versus two plant-based beverages (pea-based, and almond-based) after resistance training sessions (3 times per week for 12 months) on bone properties (bone mineral density, bone geometry), body composition, strength, and functional performance in post-menopausal women and men 50y and older.",[147],"Osteoporosis","2026-02-19",{"date":150,"type":36},"2026-02-23",{"date":152,"type":36},"2025-05-30",{"date":154,"type":22},"2027-08-30",{"name":42,"class":43},{"id":157,"slug":158,"hasResults":12,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":51,"sex":18,"minAge":163,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":23,"phases":166,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":170,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":174,"locationsCount":68},"100588688","stretching-to-improve-jumping-performance-100588688","NCT06944652","Stretching to Improve Jumping Performance","Flexibility Training (Stretching) to Improve Jumping Performance","Inclusion Criteria:\n\n* Currently involved in a sport training program\n\nExclusion Criteria:\n\n* Current or past injuries that might affect jumping performance or stretching the plantar flexors or shoulder joint","12 Years","17 Years",{"count":53,"type":22},[55],"The study involves comparison of an 8-week plantar flexor stretching program to a shoulder stretching program for improving vertical jump performance in adolescent athletes.",[169],"Vertical Jump Performance",{"date":150,"type":36},{"date":172,"type":36},"2025-04-28",{"date":60,"type":22},{"name":42,"class":43},{"id":176,"slug":177,"hasResults":12,"nctId":178,"briefTitle":179,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":18,"minAge":181,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":23,"phases":184,"briefSummary":185,"conditions":186,"keywords":191,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":204,"locationsCount":68},"100589538","pasteurized-donor-human-milk-for-hiv-exposed-infants-a-pilot-study-100589538","NCT06955715","Pasteurized Donor Human Milk for HIV-Exposed Infants: A Pilot Study","Inclusion criteria\n\n* ≥15 years of age\n* Pregnant or recently gave birth and living with HIV or is the primary caregivers of an HIV-exposed infant\n* Being followed by SHA Pediatric Infectious Disease\n* Saskatchewan resident (living within \\~150 km from the University of Saskatchewan)\n* Have a household freezer\n* Willing to participate","15 Years",{"count":183,"type":22},10,[55],"Pasteurized Donor Human Milk (PDHM) is recognized as providing vital immunological and nutritional benefits to vulnerable infants. Although PDHM is widely used in neonatal intensive care units (NICUs) to prevent infections (necrotizing enterocolitis) and improve infant health outcomes, its use for other populations, such as HIV-exposed infants, has been minimal.\n\nPasteurized donor human milk is included in the 2023 Canadian Paediatric Society clinical consensus as a potential way to provide HIV-exposed infants some of the immunological benefits of human milk in a safe manner, as opposed to exclusive formula feeding (which is currently considered the gold standard for HIV-exposed infants). These new consensus guidelines also include recommendations to support those who wish to breastfeed using a harm reduction approach (e.g., increased viral load monitoring by peds infectious diseases), given the low risk of transmission in those adhering to antiretroviral medications. However, mixed feeding (e.g., breastfeeding and provision of infant formula) is not recommended, due to the potential for micro abrasions in the gastrointestinal epithelium as a result of the protein size in infant formula (which is larger and more abrasive than in human milk), which may increase the risk of HIV transmission if the HIV virus is present in breastmilk. As such, donor milk also presents a possible solution to support those who choose to breastfeed, but who may require a temporary supplement for whatever reason (e.g., nipple cracks, mastitis, etc.), as donor milk is human milk, thus has the same size of proteins and does not pose the same risk as infant formula in damaging the epithelial layer in the gut.\n\nOverall, major obstacles remain that prevent newborns outside of the NICU from regularly having access to donor human milk. These obstacles are illustrated by the high cost of donor milk, which is not covered by government programs, and the lack of information about the clinical benefits (for both those who choose to breastfeed or formula feed), acceptability of caregivers for this feeding option, and feasibility of providing donor human milk outside of a hospital setting.\n\nThe investigators aim to determine whether giving PDHM to infants exposed to HIV is a practical possibility and learn from caregivers about any challenges associated with this feeding option. The results of this study will guide future research and a potential provincial initiative to expand access to PDHM for this population.",[187,188,189,190],"HIV","Pregnancy","Breastfeeding","Infant Feeding Practices",[192,193,194,195,196,197],"Donor Human Milk","HIV-Exposed Infants","Pasteurized Donor Milk","Infant Nutrition","Feasibility Study","HIV and Infant Feeding","2025-11-15",{"date":200,"type":36},"2025-11-19",{"date":202,"type":36},"2025-04-15",{"date":108,"type":22},{"name":42,"class":43},{"id":206,"slug":207,"hasResults":12,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":12,"sex":18,"minAge":212,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":23,"phases":215,"briefSummary":216,"conditions":217,"keywords":220,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":68},"100606678","phase-2-evaluation-of-the-safety-and-efficacy-of-neuroepo-in-subjects-with-mild-to-moderate-alzheimers-disease-100606678","NCT07178678","Evaluation of the Safety and Efficacy of NeuroEPO in Subjects With Mild to Moderate Alzheimer's Disease","A Phase II, Blinded, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of NeuroEPO in Subjects With Mild to Moderate Alzheimer's Disease Who Are Receiving Standard of Care Treatment","Inclusion Criteria:\n\n* Patients \\>= 50 years of age, to reflect the population that will be treated and to avoid younger populations who may be suffering dementia from a cause other than Alzheimer's Disease.\n* Patients with Global Deterioration Scale (GDS) between 3 to 5 points (inclusive).\n* Clinical Dementia Rating (CDR) - GS score 1-2 at screening.\n* Patients with permeable airways.\n* Patients (or caregiver, if the patient cannot) grant consent to participate in the study by signing the informed consent form.\n* Patient with caregiver is physically and mentally willing to collaborate with the investigation.\n* Mini-Mental State Examination (MMSE) score between 14 and 26 (inclusive) at screening\n\nExclusion Criteria:\n\n* Evident mental disability or other limitation that prevents the patient or caregiver from administering the study evaluations.\n* Patients with neurological symptoms or signs that suggest another cause of dementia.\n* Skull trauma or recent intracranial surgery.\n* Known clotting disorders.\n* Use of anticoagulants, a medication to prevent harmful blood clots (warfarin, heparin or NOAC).\n* Patients where coexistence of another disease or condition that may lead to significant disability (cancer, septic embolism, endocarditis, myeloproliferative disease, creatinine\\> 3 mg \u002F dl (265µmol \u002F L), hyperkalemia \\> 5.0 mmol \u002F L, chronic\u002Fsevere liver or kidney or heart disorders.\n* Patients with a history of hypersensitivity to rhEPO.\n* Patients with known allergy to any ingredients of the product.\n* Patients who present nasal irritation (sneezing) or a runny nose before starting treatment.\n* Patients who present asthma attack at the beginning of the treatment.\n* Patients receiving treatment with AChE-I or Memantine who are not stable for 12-weeks prior to screening.\n* Patients receiving treatment with psychoactive that can compromise the clinical trial results or neuropsychological tests.\n* Patients with a history of alcoholism and\u002For drug dependence.\n* Patients with chronic rhinosinusitis.\n* Have a history of abnormal nasal or sinus symptoms.\n* Have prior skull fracture or abnormality (nasal defect, deviated septum).\n* Have recent nasal trauma (fracture in the last 2 months).\n* Have any prior sinus or nose surgery (rhinoplasty).\n* Have known bleeding problem (low platelets-thrombocytopenia), recurrent nose bleeds (\\>3 year).\n* Have acute inflammation inside the nose.\n* Congenital cranial facial disorders.","50 Years",{"count":214,"type":22},90,[26],"The goal of this clinical trial is to test if NeuroEPO improves or maintains cognition in adults with mild to moderate Alzheimer's Disease using a cannula attached to a syringe for delivery. It will also learn the safety of NeuroEPO. The main questions it aims to answer are:\n\nDoes NeuroEPO lower or maintain a person's cognition who has been diagnosed with Alzheimer's Disease? What medical problems do participants have when taking NeuroEPO?\n\nResearchers will compare NeuroEPO to a placebo (a look-alike substance that contains no drug) to see if NeuroEPO works to treat Alzheimer's Disease.\n\nParticipants will:\n\nTake NeuroEPO or a placebo three times a week for one year Visit the clinic to determine eligibility, for cognitive testing and blood tests at the start and end of the trial and at 1, 2, 6 and 12 months for check ups and blood collection",[218,219],"Mild Alzheimer's Disease","Moderate Alzheimer's Disease",[221,222,223,224],"Alzheimer's Disease","NeuroEPO","EPO","ADAS-cog13","2025-09-10",{"date":227,"type":36},"2025-09-17",{"date":229,"type":22},"2025-11",{"date":231,"type":22},"2030-12",{"name":42,"class":43},{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":51,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":23,"phases":242,"briefSummary":243,"conditions":244,"keywords":249,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":260,"locationsCount":4},"100601703","assessing-the-efficacy-and-impact-of-ambient-ai-scribes-in-healthcare-100601703","NCT07113938","Assessing the Efficacy and Impact of Ambient AI Scribes in Healthcare","Assessing the Efficacy and Impact of Ambient AI Scribes in Healthcare: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Physicians from family medicine or any specialty\n* Physicians who regularly see patients in a clinic setting at least 2 days per week\n\nExclusion Criteria:\n\n* Physicians who are planning to leave their practice during the study period",{"count":241,"type":22},64,[55],"The goal of this clinical trial is to assess the impacts of ambient AI scribes on the workload and burnout in physicians who see patients in a clinic setting at least twice in a week, as well as the impacts on patient-physician interaction.\n\nThe main questions it aims to answer are:\n\n* What is the impact of ambient AI scribe use on physician workload and burnout?\n* What is the impact of ambient AI scribe use on quality of patient-physician interaction?\n\nResearchers will compare the group of physicians using the ambient AI scribes to the group not using ambient AI scribes to see if there are any significant differences.\n\nParticipants randomly assigned to Group A will make use of the AI scribe and participants randomly assigned to Group B will not use any AI scribe for the 10 working day duration of the study. They will be asked to complete a survey assessing workload and burnout immediately prior to the commencement of the study and at the end of each week of the study or 5 full working days for part time physicians. They will also invite their patients to complete a survey assessing their experience after each clinical interaction.",[245,246,247,248],"Use of Ambient AI Scribes","Patient-Phyisican Interaction","Physician Workload","Physician Burnout",[250,251,252,253],"artificial intelligence","physician workload","physician burnout","documentation quality","2025-08-02",{"date":256,"type":36},"2025-08-11",{"date":258,"type":22},"2025-08",{"date":258,"type":22},{"name":42,"class":43},{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":267,"eligibilityCriteria":268,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":269,"targetDuration":4,"studyType":23,"phases":271,"briefSummary":272,"conditions":273,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":282,"locationsCount":283},"100383761","systemic-therapy-with-a-loco-regional-treatment-in-patients-with-locally-advanced-pancreatic-cancer-100383761","NCT04276857","Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer","Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer: The SMART Study","SMART","Inclusion Criteria:\n\nAdult patients with biopsy-proven locally advanced pancreatic adenocarcinoma who are candidates for combination chemotherapy as determined by treating oncologists.\n\nExclusion Criteria:\n\n1. Pregnancy\n2. Metastatic pancreatic cancer\n3. Another active second primary cancer with the exception of squamous cell carcinoma of the skin or an in situ cancer.",{"count":270,"type":22},27,[55],"Background\n\nPancreatic cancer is one the leading causes of cancer-related death in Canada. Approximately 40 percent of patients with pancreatic cancer present with locally advanced pancreatic cancer and are not candidate for curative surgery. The optimal management of patients with locally advanced pancreatic cancer remains unknown. Most patients are treated with chemotherapy alone and role of local treatment such as radiation is not well defined. Other conventional ablative therapies such as thermal ablation and cryoablation have limited role in locally advanced pancreatic cancer due to the risk of collateral damage to the adjacent structures. Irreversible electroporation (IRE) is a novel non-thermal ablation technology that does not cause injury to nearby blood vessels, ducts, and bowel and has potential to provide longer disease control and thereby a better overall survival. The current study aims to prospectively validate effectiveness and safety of IRE in real-world patients with locally advanced pancreatic cancer.\n\nObjectives\n\n1\\) To determine 12-month progression-free survival (PFS) and 24-month overall survival rates of patients with locally advanced pancreatic cancer who are treated with combination chemotherapy and IRE and 2) to compare progression-free and overall survival of patients with locally advanced pancreatic cancer who are treated with combination chemotherapy and IRE versus combination chemotherapy alone.\n\nDesign\n\nProspective multicenter single arm study.\n\nMethods\n\nBased on the assumption of doubling of PFS of patients who are being treated with IRE and chemotherapy versus chemotherapy alone we estimated a sample of n=27 of adult patients with histologically proven non-metastatic locally advanced adenocarcinomas. Eligible patients will be recruited at the two major cancer centers in Saskatchewan. All IRE eligible patients will receive 12 weeks of induction chemotherapy and will undergo repeat imaging studies. If there is no disease progression IRE will be performed. An additional 12 weeks of chemotherapy will be recommended. Patients who are not eligible for IRE due to size criteria will receive chemotherapy at the discretion of treating oncologist till disease progression or till they become eligible for IRE. Quality of life will be assessed every three months or until disease progression.\n\nSignificance\n\nDespite progress in the management of most solid organ cancers and better outcomes, little advancement has been made in the treatment of patients with locally advanced pancreatic cancer. Unfortunately, most patients have very limited life expectancy. There is an unmet need for novel approaches in the management of patients with locally advanced pancreatic cancer. IRE in combination with chemotherapy has potential to improve local disease control and thereby improves survival and may prove a valuable tool to add in the multidisciplinary treatment of cancer. The result of this study will be used for the development of a future multicenter national phase III trials.",[274,275],"Locally Advanced Pancreatic Cancer","Irreversible Electroporation","2025-05-07",{"date":278,"type":36},"2025-05-13",{"date":280,"type":36},"2025-05-01",{"date":108,"type":22},{"name":42,"class":43},2,{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":292,"enrollmentInfo":293,"targetDuration":4,"studyType":23,"phases":295,"briefSummary":296,"conditions":297,"keywords":299,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":306,"leadSponsor":307,"locationsCount":68},"100316569","phase-2-conversion-from-unresectable-to-resectable-metastatic-colorectal-cancer-100316569","NCT03401294","Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.","Conversion From Unresectable To Resectable Liver Metastases In Patients With Liver-Only Metastatic Colorectal Cancer Treated With FOLFOXIRI Plus Bevacizumab. The Conversion Trial.","CONVERSION","Inclusion Criteria:\n\n* Adult patients, aged between 18 and 70 years with histologically proven adenocarcinoma or poorly differentiated carcinoma of the colon and rectum with unresectable liver-only metastases and no extra-hepatic disease.\n* World Health Organization (WHO) performance status of 0-1.\n* No previous chemotherapy for advanced disease.\n* Adequate functioning of the bone marrow, liver, and kidneys.\n\nExclusion Criteria:\n\n* Breastfeeding or pregnancy.\n* An active second primary cancer with the exception of squamous cell carcinoma of the skin or an in situ cancer.\n* Severe or uncompensated concomitant medical conditions.","70 Years",{"count":294,"type":22},32,[26],"Most patients with mCRC are treated with palliative chemotherapy and only a small number of patients with limited metastatic disease achieve long-term remission following metastasectomy. There is a growing need for more effective treatment in patients with liver-only mCRC to improve the rate of curative resection without compromising QOL.The current study is informed by our patient's needs. It aims to evaluate the rate of conversion therapy in patients with unresectable liver-only mCRC using the combination of FOLFOXIRI and bevacizumab and to assess the association between an early FDG-PT\u002FCT response and other clinical and pathological biomarkers and hepatic metastasectomy.",[298],"Metastatic Colorectal Cancer",[300,301,302],"Metastatic colorectal cancer","Conversion therapy","Liver Metastasectomy",{"date":304,"type":36},"2025-05-09",{"date":280,"type":36},{"date":108,"type":22},{"name":42,"class":43},{"id":309,"slug":310,"hasResults":12,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":315,"targetDuration":317,"studyType":318,"phases":4,"briefSummary":319,"conditions":320,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":68},"100502721","non-invasive-blood-pressure-monitoring-100502721","NCT05825937","Non-Invasive Blood Pressure Monitoring","Non-invasive Hemodynamic Monitoring With ClearSight in Patients Undergoing Elective Cardiac or Neurointerventional Surgery: A Prospective Observational Cohort Study","Inclusion Criteria:\n\n* written informed consent\n* undergoing elective cardiac surgery OR elective neurointerventional surgery (with standard arterial radial line for continuous blood pressure monitoring)\n\nExclusion Criteria:\n\n* undergoing emergent cardiac surgery OR emergent neurointerventional surgery",{"count":316,"type":22},62,"3 Days","OBSERVATIONAL","The purpose of this study is to evaluate an alternative way of continuously measuring blood pressure in patients coming for complex surgery. The investigators will directly compare the speed of set up and accuracy of the new ClearSight monitor to those taken by the arterial line monitor, which is the current gold standard for recording blood pressure measurements.",[321],"Blood Pressure","2025-05-06",{"date":324,"type":36},"2025-05-11",{"date":326,"type":36},"2021-06-01",{"date":328,"type":22},"2025-12-31",{"name":42,"class":43},{"id":331,"slug":332,"hasResults":12,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":4,"eligibilityCriteria":336,"healthyVolunteers":51,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":337,"targetDuration":4,"studyType":23,"phases":339,"briefSummary":340,"conditions":341,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":68},"100458637","stretching-vs-walking-for-lowering-blood-pressure-100458637","NCT05252208","Stretching vs Walking for Lowering Blood Pressure","Is Stretching Superior to Aerobic Training for Reducing Blood Pressure?","Inclusion Criteria:\n\n* Systolic blood pressure between 130 and 159 mmHg OR diastolic blood pressure between 85 and 99 mmHg\n* Able to walk unaided for 30 minutes\n* Can safely perform exercises as determined by the Get Active Questionnaire\n\nExclusion Criteria:\n\n* Not on blood pressure medication unless it has been a stable dose for 6 months and target blood pressure has not been achieved (i.e. below 140\u002F90 mmHg)\n* Smoking\n* Already performing 150 minutes or more moderate to vigorous physical activity per week\n* Already involved in a flexibility-training program (e.g. Yoga or Pilates)\n* Pregnant or lactating or planning to become pregnant during the study",{"count":338,"type":22},96,[55],"High blood pressure is a leading risk factor for cardiovascular disease. Traditionally, one of the ways to treat or prevent high blood pressure is to prescribe aerobic exercise training (i.e. brisk walking). Stretching may also be effective because it may cause changes in blood vessel stiffness and therefore reduce resistance to blood flow. The study will assess a group of individuals (i.e. 96) participating in a supervised stretching or walking program five days per week for six months to determine whether stretching is superior for reducing blood pressure. This research will contribute to recommendations about the most effective exercise programs for reducing blood pressure and risk of cardiovascular disease.",[342],"Hypertension","2025-04-17",{"date":345,"type":36},"2025-04-23",{"date":347,"type":36},"2022-03-28",{"date":349,"type":22},"2026-08-30",{"name":42,"class":43},{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":51,"sex":357,"minAge":19,"maxAge":117,"enrollmentInfo":358,"targetDuration":4,"studyType":23,"phases":360,"briefSummary":361,"conditions":362,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":370,"locationsCount":68},"100560204","phase-1-relative-bioavailability-of-two-orally-administered-cbd-formulations-in-healthy-male-adults-100560204","NCT06574100","Relative Bioavailability of Two Orally Administered CBD Formulations in Healthy Male Adults","Inclusion Criteria:\n\n1. Age 18 - 35 years old\n2. Clinical labs within the stated normal range of the Royal University Hospital Test Centre, or values outside the stated normal range that are not of clinical significance as determined by the qualified investigator.\n3. No clinically significant disease on medical history or clinically significant findings on physical examination including vital signs as determined by the qualified investigator.\n4. Ability to stay in the clinic trial unit for 13 hours on the day of each single oral dose.\n5. Ability to return for blood draws in the subsequent days.\n\nExclusion Criteria:\n\n1. History or presence of significant gastrointestinal, liver or kidney disease or any other condition known to interfere with drug pharmacokinetics including bioavailability or increase risk of adverse effects.\n2. History or presence of serious cardiovascular disease, such as ischaemic heart disease, arrhythmias, poorly controlled hypertension or severe heart failure\n3. Males whose partners are trying to conceive (i.e. male subjects intending to start a family during the study period)\n4. Lack of medically acceptable contraception by participants whose female partners have childbearing potential for the duration of the study.\n5. Personal or family history of schizophrenia or any other psychotic disorder\n6. Current or past drug or alcohol dependence or abuse\n7. Use of Cannabis-based therapy within 2 months (Participants who have previously used a Cannabis-based therapy may be included if they have a 2-month period without use of Cannabis-based therapy prior to enrolment in the study)\n8. Use of recreational Cannabis within 2 months (Participants who have previously used recreational Cannabis may be included if they have a 2-month period without use of recreational Cannabis prior to enrolment in the study)\n9. Use of psychotropic medications with serotonergic activity (e.g. Selective Serotonin Reuptake Inhibitors, Tricyclic Antidepressants, Atypical Neuroleptics) within one week\n10. Use of narcotic medications (e.g. Codeine, Morphine, Oxycontin) within one week\n11. Use of any other medication known to interact with medicinal Cannabis within one week.\n12. Allergy or known intolerance to any of the compounds within the study preparation.\n13. Resting heart rate HR \\\u003C 50 bpm or \\> 100 bpm or seated blood pressure \\\u003C 100\u002F60 or higher than 140\u002F90\n14. Inability of study participants to attend and complete all study visits\n15. Bleeding disorder\n16. Known low hematocrit","MALE",{"count":359,"type":22},20,[25],"This project is aimed at understanding whether a new fast-dissolving cheek-administered cannabidiol strip will be absorbed better into the body than cannabidiol powder. The results of this study will help guide dosage formulation choices as well as dosing regimens in NFL athletes for concussion management.",[363],"Pharmacokinetics","2025-03-25",{"date":366,"type":36},"2025-03-30",{"date":368,"type":36},"2024-10-26",{"date":229,"type":22},{"name":42,"class":43},{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":4,"eligibilityCriteria":377,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":23,"phases":379,"briefSummary":381,"conditions":382,"keywords":385,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":395,"locationsCount":68},"100306705","phase-4-ect-with-ketamine-anesthesia-vs-high-intensity-ketamine-with-ect-rescue-for-treatment-resistant-depression-100306705","NCT03272698","ECT with Ketamine Anesthesia Vs High Intensity Ketamine with ECT Rescue for Treatment-Resistant Depression","A Prospective Randomized Controlled Trial of Electroconvulsive Therapy with Ketamine Anesthesia (Standard Therapy) and High Intensity Ketamine with Electroconvulsive Therapy Rescue for Treatment-Resistant Depression - EAST HIKER Trial","Inclusion Criteria:\n\n* Montgomery Asberg Depression Rating Scale (MADRS) score of greater than 20) planned for ECT therapy.\n* Subjects must meet clinical criteria for TRD defined as failure to respond to at least 2 standard-of-care drug therapies of adequate treatment duration.\n\nExclusion Criteria:\n\n* Subjects will be ineligible if they cannot provide informed consent\n* American Society of Anesthesiology physical status score of four or greater\n* Implanted medical device with electronic parts (e.g. pacemaker, defibrillator, intrathecal pump, spinal cord stimulator, deep brain stimulator)\n* Schizoaffective disorder\n* Women of child-bearing potential will be asked to undergo a commercial urine pregnancy screening test. Those who refuse or screen positive will be excluded.\n* Allergic to any of the study drugs or their carrier components\n* Any serious physical condition prior to randomization deemed by the attending psychiatrist or consulting anesthetist to be a contraindication to ECT such as cardiovascular disease (including untreated hypertension), respiratory disease, cerebrovascular disease, intracranial hypertension (including glaucoma), or seizures.",{"count":316,"type":22},[380],"PHASE4","To determine if an high intensity ketamine with ECT rescue (HIKER) approach for treatment resistant depression will: 1) reduce patient suffering by hastening disease remission, 2) have fewer side effects, 3) reduce the need for ECT, and 4) be preferred by most patients. Half of participants will be randomized to the HIKER arm and receive high intensity ketamine treatment for eight consecutive days, and the other half will be assigned to the ECT with ketamine anesthesia (EAST) arm and receive 8 ECT treatments (2-3 treatment\u002Fweek)",[383,384],"Treatment Resistant Depression","Ketamine",[386,387,388],"ketamine","treatment-resistant depression","electroconvulsive therapy","2025-01-20",{"date":391,"type":36},"2025-01-23",{"date":393,"type":36},"2017-09-01",{"date":328,"type":22},{"name":42,"class":43},{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":402,"eligibilityCriteria":403,"healthyVolunteers":12,"sex":404,"minAge":4,"maxAge":4,"enrollmentInfo":405,"targetDuration":4,"studyType":23,"phases":407,"briefSummary":408,"conditions":409,"keywords":412,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":68},"100573824","patient-preferences-for-precision-medicine-determining-optimal-patient-quality-of-life-using-parpis-100573824","NCT06751303","Patient Preferences for Precision Medicine: Determining Optimal Patient Quality of Life Using PARPi's","Patient Preferences for Precision Medicine","4PDQ","Inclusion Criteria:\n\n* Known or suspected stage 3\u002F4 high grade serous or endometrioid ovarian cancer Able to provide oral consent and complete questionnaires in English as per study protocol\n\nExclusion Criteria:\n\n* Ineligible for Maintenace PARPi therapy Refusal to undergo HRD testing","FEMALE",{"count":406,"type":22},100,[55],"Patients with ovarian cancer with defective DNA repair mechanisms derive substantial benefit from PARP inhibitor (PARPi) maintenance therapy. Both niraparib and olaparib are effective inhibitors of PARP, which exploit already defective DNA repair mechanisms (e.g., via BRCA mutations), particularly those with homologous recombination deficiency (HRD). These two PARPis have notably different toxicity profiles, with niraparib showing many more severe side effects. In this Ovarian Cancer Canada funded study, we will implement perform HRD testing for ovarian cancer patients in Saskatchewan with response to platinum-based chemotherapy. This information will provide personalized and precision estimates about the amount of benefit that can be expected from taking a PARPi. We will evaluate both treatment outcomes and quality of life in a real-world study setting, to inform future decision-making regarding efficacy, quality of life and cost-effectiveness of PARPi therapy, specifically for niraparib.\n\nWe hypothesize that for patients who are homologous recombinant proficient (HRP), the median 32.7-month incremental benefit (in delaying cancer progression) from taking a PARPi (niraparib is the only PARPi approved in this setting) will not be seen as being value-add when balanced by the decreased quality of life that accompanies the first 6-12 weeks of therapy. We also hypothesize that for women who are HRP, that PARPi therapy will not be cost-efficient.",[410,411],"Ovarian Cancer","Quality of Life",[413,414],"PARPi","HRD testing","2024-12-26",{"date":417,"type":36},"2024-12-27",{"date":419,"type":36},"2023-09-17",{"date":421,"type":22},"2027-09-16",{"name":42,"class":43},{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":429,"targetDuration":4,"studyType":23,"phases":430,"briefSummary":431,"conditions":432,"keywords":434,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":68},"100568303","phase-4-evaluating-the-impact-of-single-dose-tiotropium-on-allergen-induced-early-asthmatic-response-100568303","NCT06679465","Evaluating the Impact of Single Dose Tiotropium on Allergen-induced Early Asthmatic Response","Inclusion Criteria:\n\n* age (years) at least 18 years\n* no confounding health issue (i.e. no health conditions, other than asthma, that would put the participant at risk or affect data integrity as determined by the principal investigator)\n* baseline FEV1 ≥ 65% of predicted normal at Visit 1\n* evidence of atopy to an allergen suitable for inhalation challenge following skin prick testing such as house dust mite, grass, cat or horse\n* fall in FEV1 of ≥ 20% at a dose of methacholine ≤ 600mcg (methacholine PD20) at Visit 1\n* positive response to allergen inhalation challenge (fall in FEV1 of ≥ 15% after inhalation of allergen at a dilution 1:32 or more dillute.\n* absence of respiratory infection for at least 4 weeks prior to Visit 1\n* absence of significant worsening of asthma that requires health care intervention or prolonged change in medication due to allergen exposure (or other trigger) for at least 4 weeks prior to Visit 1\n* women of child-bearing potential shall not be pregnant or lactating\n* non-smoker (cigarettes, vaping); ex-smoker with \\\u003C10 pack year history allowed; cannabis use will be evaluated on a case-by-case basis\n* if on as needed budesonide\u002Fformoterol therapy, no reported use within 3 weeks prior to allergen challenge\n\nExclusion Criteria:\n\n* Smoker \\>10 pack year history",{"count":183,"type":22},[380],"Evaluate single dose (2 x 2.5mcg\u002Fpuff; total dose 5mcg) effect of tiotropium administered 30 minutes prior to allergen challenge on allergen-induced EAR assessed as the maximal % fall in FEV1 after allergen inhalation compared to that of single dose (two puffs) matched placebo administered 30 minutes prior to allergen challenge.",[433],"Asthma Bronchiale",[435,436,437],"asthma","Tiotropium","Early asthmatic response","2024-11-06",{"date":440,"type":36},"2024-11-07",{"date":442,"type":22},"2025-01-01",{"date":444,"type":22},"2027-01",{"name":42,"class":43},{"id":447,"slug":448,"hasResults":12,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":4,"eligibilityCriteria":452,"healthyVolunteers":51,"sex":18,"minAge":453,"maxAge":454,"enrollmentInfo":455,"targetDuration":4,"studyType":23,"phases":457,"briefSummary":458,"conditions":459,"keywords":461,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":68},"100536470","impact-of-milk-and-yogurt-supplementation-on-bone-health-body-composition-and-gut-microbiota-in-canadian-young-adults-100536470","NCT06265246","Impact of Milk and Yogurt Supplementation on Bone Health, Body Composition, and Gut Microbiota in Canadian Young Adults","The Effects of Milk and Yogurt Supplementation on Bone Health, Body Composition, and Gut Microbiota in Canadian Young Adults: A Randomized Controlled Trial","Inclusion Criteria:\n\n* 19-30 years old\n* Dietary calcium intake below 1000mg\u002F day\n* living in the Saskatoon area (Saskatchewan, Canada)\n\nExclusion Criteria:\n\n* Calcium intake from both food and supplement above the estimated average requirement (EAR) for adults aged 19-30 years (\\>800 mg\u002Fday)\n* Total dairy intake of more than 1 serving per day\n* Body mass index greater than to 30 kg\u002Fm2\n* Medical history of metabolic bone, liver, endocrine, connective tissue, and respiratory diseases, thyroid disorders, or cancer\n* Diagnosed cases with secondary osteoporosis due to hypoparathyroidism\n* Hormonal disorders or disturbances\n* Taking medications known to influence bone mass and density (e.g., steroids, diuretics, heparin, and cancer drugs)\n* Cow's milk allergy\n* Pregnant or lactating women, or those planning to conceive during the duration of the trial","19 Years","30 Years",{"count":456,"type":22},99,[55],"Milk and dairy products contain significant amounts of nutrients that contribute to optimal health - nutrients like calcium, vitamin D, and high-quality protein. Fermented milk products or fermented dairy products are dairy foods that have been fermented with certain bacteria. Yogurt is a fermented dairy product containing millions of beneficial bacteria. In this study, the invesgitagtors will look at the effect of milk (a non-fermented dairy product) and yogurt (a fermented dairy product) supplementation on bone health and the amount of fat and muscle mass in Canadian young adults over a 24-month period. While dairy products contain significant amounts of nutrients, the scientific community does not know the impact of long-term supplementation of fermented (i.e., yogurt) or non-fermented (i.e., milk) dairy food on bone health and the amount of fat and muscle mass in young adults. To fill this knowledge gap, the investigators will recruit participants with low calcium intake and assign them to three different groups: 1) milk (intervention) group; 2) yogurt (intervention) group; and 3) control group. The investigators will ask the participants in the milk group to drink 1.5 servings (375 mL) of milk per day for 24 months. Participants in the yogurt group will consume 2 servings (350 g) of yogurt per day for 24 months. Those in the control group will continue their usual diets. Using a randomized controlled trial design, the investigators will measure bone health parameters, hormonal indices related to bone metabolism, body composition (e.g., muscle mass, fat mass), and the number and composition of bacteria living in the gastrointestinal (GI) tract. The hypothesis is that supplementation with yogurt will have more positive effects on bone health indices, particularly femoral neck BMD as the primary outcome, than milk in Canadian adults aged 19-30 years. The secondary hypothesis is that supplementation with yogurt, as a fermented milk product, will have a more beneficial effect than milk on body composition measures. The data will provide valuable information for developing targeted health initiatives and marketing strategies regarding the benefits of fermented and non-fermented dairy product consumption.",[147,460],"Obesity",[462,463,464,465,466,467,468,469],"probiotics","cultured milk products","milk","osteoporosis","obesity","gastrointestinal microbiome","body composition","yogurt","2024-08-14",{"date":472,"type":36},"2024-08-16",{"date":474,"type":22},"2024-09-01",{"date":476,"type":22},"2028-05-15",{"name":42,"class":43},{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":4,"eligibilityCriteria":484,"healthyVolunteers":12,"sex":18,"minAge":485,"maxAge":4,"enrollmentInfo":486,"targetDuration":4,"studyType":23,"phases":488,"briefSummary":489,"conditions":490,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":4},"100519704","phase-1-irreversible-electroporation-nanoknife--and-immunotherapy-for-the-treatment-of-stage-iv-colorectal-cancer-100519704","NCT06047015","Irreversible Electroporation (NanoKnife ®) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer","Immune Response to Irreversible Electroporation (NanoKnife ®) and a Checkpoint Inhibitor With or Without CpG Oligodeoxynucleotides for the Treatment of Stage IV Colorectal Cancer","Inclusion Criteria:\n\n1. Biopsy-proven colorectal liver metastases with at least one measuring \\\u003C 3.5 cm in diameter and accessible to percutaneous IRE such that a complete ablation of the lesion is possible.\n2. Prior resection of the colorectal cancer primary.\n3. The imaging has been reviewed in multi-disciplinary Rounds and the colorectal liver metastases have been deemed unresectable.\n4. Patient has undergone chemotherapy and has not converted to resectable disease.\n5. Radiologic evidence of stable disease for at least two months on systemic therapy for colorectal cancer (may have had prior partial response or disease progression)\n6. Microsattelite instability (MSI)-stable or mismatch-proficient tumors\n7. Patient has HLA phenotype of Human Leukocyte Antigen (HLA) A1 or HLA A2.\n8. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Size of the metastasis being treated with IRE \\> 3.2 cm or \\\u003C 2 cm.\n2. Size of any non-IRE-treated liver metastasis \\> 4 cm\n3. Pregnancy\n4. Major comorbid disease\n5. Active autoimmune disease\n6. Bone or brain or peritoneal metastases.\n7. MSI High disease\n8. Patients with cardiac arrhythmia other than rate controlled atrial fibrillation.\n9. Metal implant that cannot be removed within 10 cm of the area to be treated.\n10. Peritoneal disease.\n11. Poor performance status\n12. Cirrhosis","16 Years",{"count":487,"type":22},12,[25,26],"The goal of this pilot clinical trial is to learn about the combination of immune boosting drugs and irreversible electroporation (IRE) in patients with colon cancer that has spread to the liver (metastasis). The main questions it aims to answer are:\n\n1. to document the rate of complications associated with combining IRE with immune boosting drugs.\n2. After one liver metastasis is treated with IRE and immune boosting drugs, what is the change in the size of the non-IRE-treated liver metastases?\n3. What is the immune response (measured in a blood sample) when IRE is combined with one or two types of immune boosting drugs?",[491],"Liver Metastasis Colon Cancer","2024-08-06",{"date":494,"type":36},"2024-08-09",{"date":496,"type":22},"2025-07",{"date":498,"type":22},"2028-12",{"name":42,"class":43},{"id":501,"slug":502,"hasResults":12,"nctId":503,"briefTitle":504,"officialTitle":505,"acronym":4,"eligibilityCriteria":506,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":507,"targetDuration":4,"studyType":23,"phases":509,"briefSummary":510,"conditions":511,"keywords":513,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":526,"locationsCount":68},"100542388","chronic-migraines-and-neurofdeeback-mindfulness-100542388","NCT06342219","Chronic Migraines and Neurofdeeback Mindfulness","Study Protocol for a Randomized Controlled Trial of Neurofeedback Mindfulness in Chronic Migraines","Inclusion Criteria:\n\n* have a diagnosis of chronic migraine from a clinician or have met the criteria for a chronic migraine diagnosis based on ICHD-3\n* reside in Saskatoon area\n* have a smartphone and internet connection for accessing the MUSE app\n* have no frequent background experience of meditation\n\nExclusion Criteria:\n\n* Comorbidity of Raynaud's syndrome or diabetes\n* Current use of a preventative migraine treatment over 6 months",{"count":508,"type":22},135,[55],"As the second phase of our study on migraine headaches and neurofeedback mindfulness, we will explore how chronic migraineurs will benefit from a long term practice (8 weeks) of neurofeedback mindfulness compared to a similar attention group and a waitlisted group. This randomized controlled trial will also explore if migrianuers could decrease their dependence on medicine intake after completion of the study.",[512],"Chronic Migraine, Headache",[514,515,516,517,518],"neurofeedback mindfulness","headache management self-efficacy","chronic migraines","dependence behaviours","migraine severity","2024-03-26",{"date":521,"type":36},"2024-04-02",{"date":523,"type":22},"2024-12",{"date":525,"type":22},"2026-06",{"name":42,"class":43},{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":533,"eligibilityCriteria":534,"healthyVolunteers":51,"sex":18,"minAge":535,"maxAge":163,"enrollmentInfo":536,"targetDuration":4,"studyType":318,"phases":4,"briefSummary":538,"conditions":539,"keywords":541,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":68},"100538208","canadian-bone-strength-development-study-100538208","NCT06287840","Canadian Bone Strength Development Study","Canadian Bone Strength Development in Children With Type 1 Diabetes Study","CanBSDS","Children with Type-I Diabetes:\n\nInclusion Criteria\n\n* Females: 10-11 years old.\n* Males: 11 - 12 years old.\n* Diagnosed with type-1 diabetes for at least 6 months.\n* Capacity to give informed consent (patient and parent\u002Fguardian). Children with the capacity to give assent will do so in addition to parental consent.\n\nExclusion Criteria\n\n* Consuming any medications or have additional illnesses associated with bone health, osteoporosis (including renal disease, celiac disease, hypogonadism, hyperthyroidism) or altered physical growth (precocious puberty).\n* Have gone through adolescent growth spurt at study entry.\n\nControl Group (Typically Developing Children):\n\nInclusion Criteria\n\n* Females: 10-11 years old.\n* Males: 11 - 12 years old.\n* Capacity to give informed consent (patient and parent\u002Fguardian). Children with the capacity to give assent will do so in addition to parental consent.\n\nExclusion Criteria\n\n* Have an illness or are taking medications influencing bone health or physical growth.\n* Evidence of pathologic low trauma or vertebral fracture(s).\n* Have gone through adolescent growth spurt at study entry.","10 Years",{"count":537,"type":22},204,"The goal of this project is to learn about differences in bone development between children with and without type-1 diabetes (T1D). The main questions this study aims to answer are:\n\n1. Assess how and when sex-specific bone developmental trajectories in the leg and arm will differ between children with T1D and control cohorts relative to the critical period of rapid skeletal growth in puberty. It is hypothesized that children with T1D will have inferior bone development, particularly lower gains in bone strength.\n2. Assess why bone trajectories differ between T1D and control cohorts by identifying the role of body composition, site-specific muscle force and physical activity on differences in bone properties in female and male children with and without T1D. It is hypothesized that children with T1D will have lower gains in lean mass, muscle force, number of daily bone impacts and minutes of moderate-vigorous physical activity and will be associated with inferior gains in bone development.\n3. Assess why T1D may impair sex-specific bone development by exploring the role of disease-related factors (e.g., duration, glucose control, hormones and markers of bone turnover) and fracture history on bone trajectories of children with T1D. It is hypothesized that longer exposure to T1D, poorer glucose control, alterations in hormones, lower bone formation markers and higher history of fracture will be negatively associated with bone trajectories of children with T1D.\n\nParticipant's physical growth, bone growth, muscle strength, physical activity and nutrition habits will be assessed and followed up annually for up to 4 years.",[540],"Type-1 Diabetes",[540,542,543,544,545],"Bone","Growth","Children","Physical Activity","2024-03-04",{"date":548,"type":36},"2024-03-06",{"date":550,"type":22},"2024-04-01",{"date":552,"type":22},"2028-12-31",{"name":42,"class":43},{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":4,"eligibilityCriteria":560,"healthyVolunteers":12,"sex":404,"minAge":19,"maxAge":4,"enrollmentInfo":561,"targetDuration":4,"studyType":23,"phases":563,"briefSummary":565,"conditions":566,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":283},"100535201","phase-3-effect-of-intravenously-iron-infusion-on-the-prevention-and-treatment-of-anemia-in-ovarian-cancer-100535201","NCT06248749","Effect of Intravenously Iron Infusion on the Prevention and Treatment of Anemia in Ovarian Cancer","The Effect Of Intravenous Iron In Treating Anemia In Ovarian Cancer Patients In Saskatchewan: A Phase-III, Open-Label, Randomized Trial (IIOVS-01)","INCLUSION CRITERIA:\n\nParticipants are eligible to be included in the study only if all of the following criteria apply:\n\n1. Age and Sex: Female participants aged 18 years or more (\\>\u002F=18 years) at the time of informed consent.\n2. Type of Participant: Participants who are willing and able to comply with all scheduled visits, laboratory tests, lifestyle considerations, treatment plan, and any other study procedures.\n3. Disease Characteristics: Histologically confirmed primary epithelial invasive ovarian cancer of any grade, including serous, mucinous, endometrioid, clear cell, transitional, squamous and carcinosarcoma. Cancer must be FIGO stage IC-IV.\n4. Presence of measurable disease per RECIST v1.1, as assessed by investigator and evidenced by available baseline tumor scan. At least 1 target lesion of 10mm.\n\n   Note: Baseline Scan is defined as the last scan prior to the date of randomization.\n5. Patients should be eligible for active cancer treatment ECOG less or equal to 2 and life expectancy must be more than 6 months.\n6. Received no more than two (2) systemic lines of chemotherapy (to allow for a \\~3 years follow up).\n7. Patients on any active cancer treatment or with history of previous chemotherapy, surgery, radiation, PARP (Poly-ADP Ribose polymerase), biologics and hormonal treatment.\n8. Patients on neoadjuvant, adjuvant, advanced cancer treatment.\n9. Perioperative patients having upfront surgery (can be randomized after frozen section) or at interval or secondary debulking surgery.\n10. Informed Consent: Capable of giving signed informed consent.\n\nExclusion Criteria\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n1. Patients would not consent for IV iron infusion or blood transfusion (Example: Jehovah's Witness).\n2. History of known severe hypersensitivity to IV iron transfusion with the study iron products.\n3. Medical conditions with contraindication to IV iron infusion or blood transfusion (Example:\n\n   iron overload, hemosiderosis, decompensated liver cirrhosis or active hepatitis.)\n4. Palliative patients with life expectancy 6 months or less.",{"count":562,"type":22},200,[564],"PHASE3","Cancer related anemia (CRA) is a common sign occurring in more than 30% of patients at diagnosis, prior to initiation of antineoplastic therapy. Anemia is known to impact survival, disease progression, treatment efficacy, and the patient's quality of life.\n\nProinflammatory cytokines, mainly IL-6, which are released by both tumor and immune cells, play a pivotal action in CRA etiopathogenesis: they promote alterations in erythroid progenitor proliferation, erythropoietin (EPO) production, survival of circulating erythrocytes, iron balance, redox status, and energy metabolism, all of which can lead to anemia. Chronic inflammatory conditions such as cancer influences a compromised nutritional status, which in-turn may contribute to anemia.\n\nThis study aims to study the role of intravenous (IV) iron infusion in the management of anemia presented in patients previously treated or currently being treated for ovarian cancer. The study aims to identify the safety and efficacy of IV iron infusion on anemia in ovarian cancer patients, and the effect on quality of life and overall survival",[567],"Anaemia in Ovarian Carcinoma","2024-02-05",{"date":570,"type":36},"2024-02-08",{"date":572,"type":22},"2024-02-29",{"date":574,"type":22},"2029-12-01",{"name":42,"class":43},{"id":577,"slug":578,"hasResults":12,"nctId":579,"briefTitle":580,"officialTitle":580,"acronym":4,"eligibilityCriteria":581,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":582,"enrollmentInfo":583,"targetDuration":4,"studyType":23,"phases":585,"briefSummary":586,"conditions":587,"keywords":589,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":598,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":604,"locationsCount":68},"100397741","phase-1-evaluation-of-irdye800cw-nimotuzumab-in-lung-cancer-surgery-100397741","NCT04459065","Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery","Inclusion Criteria:\n\n* Surgically resectable Stage I and II non-small cell lung cancer\n* Able to give informed consent\n* Age ≥ 18 and ≤ 80 years old\n* Adequate cardiopulmonary reserve to undergo lung resection as determined by operating surgeon\n* No prior history of malignancy\n* No neoadjuvant therapy\n* Karnofsky performance status of at least 70% or Eastern Cooperative Oncology Group (ECOG)\u002FZubrod level 0-2\n* Hemoglobin (hgb) ≥ 90 g\u002FL\n* White blood cell count (WBC) \\> 3 x 109\u002FL\n* Platelet count (plt) ≥ 100 x 109\u002FL\n* Serum creatinine ≤ 1.5 times upper reference range\n\nExclusion Criteria:\n\n* Received anti-EGFR antibody therapy (cetuximab, panitumumab, necitumumab) within 60 days prior to trial drug\n* Pregnant or nursing\n* Known history of hypersensitivities or allergic reactions to antibodies or NSO derived products\n* Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment\n* Subjects receiving class IA (quinidine, procainamide) or class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents\n* Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis\n* Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug","80 Years",{"count":584,"type":22},36,[25,26],"The purpose of this study is to determine the safety, optimal dose and imaging time of the investigational product, IRDye800CW-nimotuzumab for use as a near infrared imaging probe for image-guided surgery during lung cancer resection. IRDye800CW-nimotuzumab targets cancer cells over-expressing EGFR, allowing tumors to be visualized and may help surgeons better identify cancer during surgery.",[588],"Lung Cancer",[590,591,592,593,594,595,596],"IRDye800CW","Nimotuzumab","Lung cancer","EGFR","Near infrared","Image guided surgery","Optical imaging","2024-01-05",{"date":599,"type":36},"2024-01-09",{"date":601,"type":36},"2020-09-01",{"date":603,"type":22},"2026-10",{"name":42,"class":43},{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":4,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":582,"enrollmentInfo":612,"targetDuration":4,"studyType":23,"phases":614,"briefSummary":615,"conditions":616,"keywords":618,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":625,"startDateStruct":626,"completionDateStruct":628,"leadSponsor":630,"locationsCount":68},"100380555","phase-1-evaluation-of-89zr-dfo-nimotuzumab-for-non-invasive-imaging-of-egfr-cancers-by-positron-emission-tomography-pet-100380555","NCT04235114","Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET)","Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR Positive Cancers by Positron Emission Tomography (PET)","Inclusion Criteria:\n\n* Male or female between 18 and 80 years old.\n* EGFR-positive cancer defined by a board certified pathologist\n* Primary or metastatic lesion size \\>= 1.5 cm as determined by imaging studies (ultrasonography, mammography, CT or MRI) or physical examination.\n* Able to give informed consent.\n* Not currently pregnant or nursing: If female subject must be surgically sterile (has had a documented bilateral oophorectomy and\u002For documented hysterectomy), post-menopausal (cessation of menses for \\> 1 year), non-lactating, or of childbearing potential for whom a urine pregnancy test is negative when taken within the 24 h before administration of 89Zr-DFO-nimotuzumab.\n* WHO performance status of 0 - 2\n* Patients naïve to anti-EGFR antibodies treatment.\n\nExclusion Criteria:\n\n* Unable to tolerate 60 min of PET imaging per session.",{"count":613,"type":22},14,[25,26],"Over-expression of Epidermal Growth Factor Receptor (EGFR) on cells occurs in all aggressive cancers of epithelial origin. Existing tests for monitoring EGFR expression are invasive and not reliable. There needs to be a better way to measure EGFR expression in cancerous tumors to better tailor cancer treatments.\n\nThis clinical trial aims to demonstrate the feasibility of imaging cancers that express EGFR using 89Zr-DFO-nimotuzumab and Positron Emission Tomography (PET)\u002FComputerized Tomography (CT). By non-invasively imaging the status of EGFR, 89Zr-DFO-nimotuzumab could be used to assist in the identification of patients who are likely to respond to anti-EGFR treatments, including nimotuzumab. The hypothesis is that 89Zr-DFO-nimotuzumab will accumulate to tumors over-expressing EGFR making them visible when imaged with PET\u002FCT. This hypothesis will be tested in this study, along with the optimal imaging time and diagnostic ability.",[588,617],"Colorectal Cancer",[619,591,592,620,593,621,622,623,624],"89Zr","Colorectal cancer","PET","PET\u002FCT","Imaging","89Zr-DFO-nimotuzumab",{"date":599,"type":36},{"date":627,"type":36},"2020-02-01",{"date":629,"type":22},"2026-12",{"name":42,"class":43},""]